Candriam SCA’s Omnicell OMCL Stock Holding History

Candriam SCA’s Portfolio OMCL Stock Details OMCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,743	Closed	-$472K	–	828
2023 Q1	$472K	Buy	+8,743	New	+$482K	﹤0.01%	780

Other funds holding OMCL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

GCM

Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return

Candriam SCA's OMCL Position: Q2 2023 in Review

Candriam SCA sold out of Omnicell (OMCL) in Q2 2023, closing a stake of 8,743 shares — an estimated $472K sold.

Candriam SCA first reported a position in OMCL in Q1 2023 and held it in 1 quarter. The position peaked at $472K in Q1 2023. 313 funds tracked by Wall St. Rank hold OMCL as of Q2 2023.

Candriam SCA reported no remaining Omnicell position as of Q2 2023 after selling out during the quarter.
Candriam SCA sold 8,743 Omnicell shares in Q2 2023, an estimated $472K.
Candriam SCA first reported a position in Omnicell in Q1 2023 and held it in 1 quarter.
Candriam SCA's Omnicell position peaked at $472K in Q1 2023.
313 funds tracked by Wall St. Rank held Omnicell as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.